Vicuron Anidulafungin User Fee Extended; Dalbavancin NDA Coming 2H 2004
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
FDA’s request for additional bioavailability data on Vicuron’s anidulafungin has extended the user fee goal date to May 25.